Allarity Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Allarity Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 2,429,051% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than almost all Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 99% of its market value (net cash). Higher than 88% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-10.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 54% of Healthcare companies in United States.
Cash Cushion Ratio
+99%Cash, after subtracting all debt, equals 99% of its market value (net cash).
Higher than 88% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Allarity Therapeutics, Inc. made a loss over the last year. Allarity Therapeutics, Inc. owes $0.89 for every $1 it owns. Allarity Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAllarity Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.81The share price is 3.81 times Allarity Therapeutics, Inc.'s book value per share, higher than 64% of Healthcare companies in United States.
Market cap
$13 MThe total market value of all of Allarity Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 85% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$4 MWhat Allarity Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.22Net worth divided by the number of shares. The share price of $0.85 is 3.8 times this, which is the P/B above.
Return on equity (ROE)
-157.1%Allarity Therapeutics, Inc. lost 157.1% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
Owes vs Owns
0.89×Allarity Therapeutics, Inc. owes $0.89 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Dividend yield
NoneAllarity Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAllarity Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-3509.7%Allarity Therapeutics, Inc. lost $3510 for every $100 of revenue.
Interest cover
Not coveredAllarity Therapeutics, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAllarity Therapeutics, Inc. held $13 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Allarity Therapeutics, Inc.: $13 M ÷ $4 M (30 Jun 2026) = 3.8.
What is Allarity Therapeutics, Inc.'s return on equity?
Allarity Therapeutics, Inc. lost 157.1% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
How much does Allarity Therapeutics, Inc. owe compared with what it owns?
Allarity Therapeutics, Inc. owes $0.89 for every $1 it owns (high), higher than 82% of Healthcare companies in United States.
Does Allarity Therapeutics, Inc. pay a dividend?
No. Allarity Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.